Page 124 - TD-4-1

Tumor Discovery Pyrotinib and capecitabine in HER2-negative recurrence

A B C

D E F

Figure 3. Recurrent lesion image and histopathology. (A) Image of the recurrent lesion on the left chest wall. (B) Hematoxylin–eosin (H&E) staining of the
excised recurrent lesion revealed invasive ductal carcinoma (×200 magnification). (C) Positive estrogen receptor immunohistochemistry findings in the
recurrent lesion (×200 magnification). (D) Immunohistochemistry examination of the recurrent lesion revealed a HER2 score of 2+ (×400 magnification).
(E) Fluorescence in situ hybridization revealed HER2 gene negative (HER2/CEP17 ratio: 1.33) recurrent lesion (×1000 magnification). (F) Post-treatment
image of the left chest wall lesion after one cycle of pyrotinib plus capecitabine.
Abbreviation: HER2: Human epidermal growth factor receptor 2.

Figure 4. Diagnosis and treatment summary of the present case

3. Discussion assessments enable tailored disease treatments at the
molecular level. The patient in the presented case was
Tumor heterogeneity often leads to therapeutic initially diagnosed with left breast cancer. The primary
refractoriness, posing significant challenges in cancer lesion, post-operative specimen, and recurrent lesion
treatment. Considering the dynamic and diverse nature were all found to consistently exhibit high ER expression.
18
of cancer, periodic evaluation of individual patients, PR expression declined to near absence, whereas HER2
specific lesions, and distinct sites is imperative. These expression remained low. FISH test results for HER2

Volume 4 Issue 1 (2025) 116 doi: 10.36922/td.4093